Study of afimkibart and other medicines in ulcerative colitis
Treatments studied
Part of Digestive system clinical trials.
This study looks at how afimkibart affects the way your body processes certain other medicines. It is for people with moderate to severe ulcerative colitis and helps researchers understand how to use this treatment safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must weigh at least 40 kg (about 88 pounds).
- You must agree to use contraception as required by the study.
- You must have a confirmed diagnosis of ulcerative colitis, with active disease seen on a scope.
- Your ulcerative colitis must be moderately to severely active, with a specific score from a colonoscopy or sigmoidoscopy.
- You cannot have Crohn's disease, certain types of colitis, or a history of fistulas or abscesses.
- You cannot have an ostomy or ileoanal pouch, primary sclerosing cholangitis, or recent substance abuse.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called MK-8690 for people with moderate to severe ulcerative colitis (UC) who haven't responded well to other treatments or can't tolerate them. The study aims to see if the drug can help control UC symptoms safely.
This trial is testing a new medication called afimkibart (RO7790121) for people with moderate to severe ulcerative colitis. It aims to see if this treatment can help reduce inflammation and improve symptoms in people who haven't had success with other therapies.
This study tests a new drug called afimkibart in children with moderate to severe ulcerative colitis who haven't responded well to other treatments. It aims to see how well the drug works and if it's safe for children.
This trial tests a new medicine called afimkibart for people with moderately to severely active Crohn's disease that has not responded well to other treatments. It aims to see if the medicine can safely reduce inflammation and improve symptoms.
This study tests an experimental drug called afimkibart for people with moderate to severe Crohn's disease who haven't responded well to other treatments. The goal is to see if the drug can help control symptoms and reduce inflammation over time.
This trial tests a medicine called afimkibart for children with moderately to severely active Crohn's disease. It aims to see how well the drug works and how safe it is when used for both starting and ongoing treatment.
Hear when a new Active Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.